Don Wetherhold, Chief Executive Officer of Aprecia says in a press release:
“By combining 3DP technology with a highly-prescribed epilepsy treatment, SPRITAM is designed to fill a need for patients who struggle with their current medication experience.”
ZipDose Technology allows patients to take higher dosages, up to 1,000 mg in a single dose resulting in an enhanced patient experience. Additionally, SPRITAM requires no measurement since each dose is individually packaged, making it easy to carry the medication on the go. This is groundbreaking news for the pharmaceutical industry and for those who suffer from epilepsy.
Aprecia expects SPRITAM is to be available in the first quarter of 2016.
The implementation of 3D-printing in the medical field is nothing new. Many companies are exploring ways that they can implement this technology. L'Oreal is one company who is using this technology to print human skin.